439 related articles for article (PubMed ID: 24287065)
41. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
42. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
43. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
44. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
45. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
[TBL] [Abstract][Full Text] [Related]
46. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
47. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
48. Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma.
Gordon LI
J Natl Compr Canc Netw; 2017 May; 15(5S):716-718. PubMed ID: 28515253
[TBL] [Abstract][Full Text] [Related]
49. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation.
Baxley AA; Kumm DE; Bishop CB; Medina PJ; Holter-Chakrabarty J
J Oncol Pharm Pract; 2013 Sep; 19(3):279-83. PubMed ID: 23154572
[TBL] [Abstract][Full Text] [Related]
50. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Rubinstein PG; Moore PC; Rudek MA; Henry DH; Ramos JC; Ratner L; Reid E; Sharon E; Noy A;
AIDS; 2018 Mar; 32(5):605-611. PubMed ID: 29280762
[TBL] [Abstract][Full Text] [Related]
51. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
52. Brentuximab vedotin for Hodgkin lymphoma who had failed allogeneic stem cell transplantation: a multicenter retrospective study.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):12-4. PubMed ID: 25768995
[No Abstract] [Full Text] [Related]
53. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French Name Patient Program experience in 241 patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):4-5. PubMed ID: 25768991
[No Abstract] [Full Text] [Related]
54. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.
Sasse S; Rothe A; Goergen H; Eichenauer DA; Lohri A; Kreher S; Jäger U; Bangard C; Kuhnert G; Böll B; von Tresckow B; Engert A
Leuk Lymphoma; 2013 Oct; 54(10):2144-8. PubMed ID: 23402268
[TBL] [Abstract][Full Text] [Related]
55. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
56. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
[TBL] [Abstract][Full Text] [Related]
58. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
Cao H; Yamamoto K; Yang LX; Weber R
Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
[TBL] [Abstract][Full Text] [Related]
59. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin.
Cao ZG; Zhou HW; Peng CJ; Liu M; Du Y; Yang QM
Chin J Cancer; 2013 Sep; 32(9):520-3. PubMed ID: 23544448
[TBL] [Abstract][Full Text] [Related]
60. Brentuximab Vedotin (SGN-35).
Katz J; Janik JE; Younes A
Clin Cancer Res; 2011 Oct; 17(20):6428-36. PubMed ID: 22003070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
